Latest Trials Latest NewsFAQ

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin degludec
Drug: insulin glargine
Drug: insulin aspart

First Posted Date: 2009-09-23

Last Posted Date: 2017-04-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 629

Registration Number: NCT00982228

Locations: 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom

Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin degludec/insulin aspart
Drug: insulin detemir
Drug: insulin aspart

First Posted Date: 2009-09-17

Last Posted Date: 2017-03-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 548

Registration Number: NCT00978627

Locations: 🇬🇧
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom

A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers

Phase 1

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Drug: liraglutide

First Posted Date: 2009-09-16

Last Posted Date: 2017-07-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 49

Registration Number: NCT00978393

Locations: 🇳🇱
Novo Nordisk Investigational Site, Maastricht, Netherlands

Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725

Phase 3

Completed

Conditions: Congenital Bleeding Disorder
Congenital FXIII Deficiency

Interventions: Drug: catridecacog

First Posted Date: 2009-09-16

Last Posted Date: 2018-01-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 63

Registration Number: NCT00978380

Locations: 🇬🇧
Novo Nordisk Investigational Site, Newcastle upon Tyne, United Kingdom

A Trial Investigating the Pharmacokinetic (Mode of Action in the Body) and Safety Profiles of NN1250 (Insulin Degludec) in Subjects With Various Degrees of Impaired Liver Function and in Subjects With Normal Liver Function

Phase 1

Completed

Conditions: Healthy
Diabetes

Interventions: Drug: insulin degludec

First Posted Date: 2009-09-14

Last Posted Date: 2017-01-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 12

Registration Number: NCT00976326

Locations: 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia

Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin glargine
Drug: insulin degludec
Drug: insulin aspart

First Posted Date: 2009-09-04

Last Posted Date: 2017-04-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1006

Registration Number: NCT00972283

Locations: 🇹🇷
Novo Nordisk Investigational Site, Mersin, Turkey

Comparison of Two NN1250 Formulations in Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: insulin degludec

First Posted Date: 2009-08-26

Last Posted Date: 2015-09-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 27

Registration Number: NCT00966368

Locations: 🇺🇸
Novo Nordisk Clinical Trial Call Center, Chula Vista, California, United States

A Trial Assessing Changes in Blood Sugar and the Number of Periods Where Supplementation of Carbohydrate is Needed to Treat Low Blood Sugar, During Two Different Treatment Regimens of NN1250 in Type 1 Diabetics

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes

Interventions: Drug: insulin degludec
Drug: placebo

First Posted Date: 2009-08-25

Last Posted Date: 2013-11-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 18

Registration Number: NCT00964964

A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin degludec
Drug: insulin glargine

First Posted Date: 2009-08-25

Last Posted Date: 2017-01-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 27

Registration Number: NCT00964418

Locations: 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria

A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes

Interventions: Drug: insulin degludec
Drug: insulin glargine

First Posted Date: 2009-08-18

Last Posted Date: 2017-10-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 54

Registration Number: NCT00961324

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy